Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker BBNX
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 9, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | Guy Levy | 4.83M | 8.7% | SCHEDULE 13G/A ↗ |
| Nov 9, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | Soleus GP, LLC | 4.79M | 8.6% | SCHEDULE 13G/A ↗ |
| Nov 9, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | Soleus Capital Management, L.P. | 4.79M | 8.6% | SCHEDULE 13G/A ↗ |
| Nov 9, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | Soleus Capital Group, LLC | 3.78M | 6.8% | SCHEDULE 13G/A ↗ |
| Nov 9, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | Soleus Capital, LLC | 3.78M | 6.8% | SCHEDULE 13G/A ↗ |
| Nov 9, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | Soleus Capital Master Fund, L.P. | 3.78M | 6.8% | SCHEDULE 13G/A ↗ |
| Nov 9, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | Soleus PE GP II, LLC | 1.00M | 1.8% | SCHEDULE 13G/A ↗ |
| Nov 9, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | Soleus Private Equity GP II, LLC | 1.00M | 1.8% | SCHEDULE 13G/A ↗ |
| Nov 9, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | Soleus Private Equity Fund II, L.P. | 1.00M | 1.8% | SCHEDULE 13G/A ↗ |
| Oct 7, 2026 | SCHEDULE 13G | BBNX Beta Bionics, Inc. | T. Rowe Price Associates, Inc. | 8.94M | 16.6% | SCHEDULE 13G ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | Mark C. Wehrly | 595,000 | 1.3% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | John R. Warren | 595,000 | 1.3% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | Andrew J. M. Spokes | 595,000 | 1.3% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | Daniel S. Short | 595,000 | 1.3% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | Edric C. Saito | 595,000 | 1.3% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | Roberts, Jr., Thomas G. | 595,000 | 1.3% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | Luo Patrick (Cheng) | 595,000 | 1.3% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | Michael G. Linn | 595,000 | 1.3% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | David T. Kim | 595,000 | 1.3% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | Avner A. Husen | 595,000 | 1.3% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | Nicolas Giauque | 595,000 | 1.3% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | Varun N. Gehani | 595,000 | 1.3% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | Hannah E. Dunn | 595,000 | 1.3% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | Philip D. Dreyfuss | 595,000 | 1.3% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | Joshua J. Dapice | 595,000 | 1.3% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | Farallon F5 (GP), L.L.C. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | Farallon Institutional (GP) V, L.L.C. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | Farallon Partners, L.L.C. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | Farallon Capital F5 Master I, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | Farallon Capital (AM) Investors, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | Farallon Capital Offshore Investors II, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | Four Crossings Institutional Partners V, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | Farallon Capital Institutional Partners III, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | Farallon Capital Institutional Partners II, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | Farallon Capital Institutional Partners, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | Farallon Capital Partners, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | Zone Healthcare Holdings, LLC | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | Farallon Capital Management, L.L.C. | 595,000 | 1.3% | SCHEDULE 13G/A ↗ |
| Jul 24, 2026 | SCHEDULE 13G | BBNX Beta Bionics, Inc. | Divisadero Street Capital, LLC | 3.07M | 6.9% | SCHEDULE 13G ↗ |
| Jul 24, 2026 | SCHEDULE 13G | BBNX Beta Bionics, Inc. | Divisadero Street Partners GP, LLC | 2.61M | 5.9% | SCHEDULE 13G ↗ |
| Jul 24, 2026 | SCHEDULE 13G | BBNX Beta Bionics, Inc. | Divisadero Street Partners, L.P. | 2.61M | 5.9% | SCHEDULE 13G ↗ |
| Jul 24, 2026 | SCHEDULE 13G | BBNX Beta Bionics, Inc. | William Zolezzi | 3.07M | 6.9% | SCHEDULE 13G ↗ |
| Jul 24, 2026 | SCHEDULE 13G | BBNX Beta Bionics, Inc. | Divisadero Street Capital Management, LP | 3.07M | 6.9% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | Robin C. John | 5.95M | 13.4% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | Finny Kuruvilla, M.D., Ph. D. | 5.95M | 13.4% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | Eventide Asset Management, LLC | 5.95M | 13.4% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | Roderick Wong | 2.00M | 4.5% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | RTW Investments, LP | 2.00M | 4.5% | SCHEDULE 13G/A ↗ |
| May 12, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | Mark C. Wehrly | 3.61M | 8.1% | SCHEDULE 13G/A ↗ |
| May 12, 2026 | SCHEDULE 13G/A (amended) | BBNX Beta Bionics, Inc. | John R. Warren | 3.61M | 8.1% | SCHEDULE 13G/A ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 11:10 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances